Zepbound (2.5mg) for weight loss

Zepbound (tirzepatide) is an injectable drug for weight loss in those with obesity or those with overweight and a weight-related condition Zepbound 2.5mg  for weight loss.

What is Zepbound?

Zepbound is a new, long-term option for managing body weight that was approved by the FDA in late 2023. It’s a once-weekly, injectable medication that has the same active ingredient as the Type 2 diabetes treatment Mounjaro (tirzepatide).

Zepbound (2.5mg) for weight loss

In a clinical study supported by Eli Lilly and published in 2022, Zepbound helped participants lose an average of 34 lbs to 48 lbs after 72 weeks (16.5 months). About a third of people taking the highest dose lost up to 25% of their initial body weight, or more than 58 lbs.

Zepbound mimics the GIP and GLP-1 hormones that a person’s stomach releases when they eat. These hormones can slow down digestion and decrease a person’s appetite, eventually helping Trusted Source a person lose weight. However, people using Zepbound must also eat a reduced calorie diet and exercise regularly.

Zepbound is for people who have:

• obesity — a body mass index (BMI) of 30 or more
• overweight — a BMI of 27 or more — and at least one weight-related health condition, such as high blood pressure, type 2 diabetes, or high cholesterol

There are six Zepbound doses available Respectively;

• 2.5 mg
• 5 mg
• 7.5 mg
• 10 mg
• 12.5 mg
• 15 mg

A person typically takes one dose per week.

A doctor will recommend which dose a person should start with. Generally, a person will start on the lowest dose of 2.5 mg and gradually increase it if necessary.